Hip Replacement Devices MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy MaterialBy Fixation TechniqueBy Age Group
Full title & scope — all 5 axes with their segments
Hip Replacement Devices Market Size, Share & Industry Analysis, By Type (Primary HIP Replacement, Partial HIP Replacement, Revision HIP Replacement, HIP Resurfacing), By Application (Hospitals, Ambulatory Surgical Centers), By Material (Metal-on-Polyethylene, Ceramic-on-Polyethylene, Ceramic-on-Ceramic, Metal-on-Metal), By Fixation Technique (Cementless, Cemented, Hybrid), By Age Group (65 Years and Above, Below 65 Years), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from unit volumes and realised prices. Base-year procedure volumes are derived from national joint-replacement registries and hospital discharge data across the largest markets, split by primary, revision, partial and resurfacing procedure type, and multiplied by average selling prices for the implant systems used in each procedure, sourced from tender and reimbursement schedules. Bearing-surface and fixation-technique mix is layered onto that volume base since price varies materially by material and fixation choice. The resulting bottom-up total is then checked against disclosed revenue for the named implant manufacturers; where a gap appears, the correction is made to the underlying volume or price assumption driving the bottom-up build, not by averaging in a separate top-down figure.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research targets the commercial and clinical-purchasing roles that actually decide which implant system a hospital or ambulatory center stocks: orthopedic surgeons, hospital procurement and materials-management leads, group-purchasing-organization category managers, and the regulatory-affairs staff at implant manufacturers who track clearance timelines. Distributor and tender-desk contacts are included in markets where devices reach hospitals through a distributor rather than direct sales. Sampling is weighted toward the United States, Germany and Japan, where registry reporting and reimbursement data are most granular, with additional coverage in China and Brazil to capture the procurement dynamics of large, fast-growing but less transparent markets.
Desk research draws on national and regional joint-replacement registries, including the American Joint Replacement Registry and the UK National Joint Registry, which publish annual procedure counts and implant-type breakdowns. FDA 510(k) and CE-mark clearance databases are used to track new implant approvals and bearing-surface trends. Hospital procurement is triangulated against Centers for Medicare and Medicaid Services procedure and reimbursement schedules, customs trade data filed under the relevant orthopedic-implant HS codes for cross-border shipment volumes, and the disclosed segment revenue in the annual filings of the publicly listed implant manufacturers named in this report.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected procedure-volume growth, driven by aging-population trends and rising osteoarthritis prevalence, combined with an assumed continuation of the outpatient shift as regional anesthesia and rapid-recovery protocols extend eligibility for same-day discharge. Bearing-surface and fixation mix is projected to continue shifting toward cementless fixation and ceramic bearings as clinical evidence accumulates. Average selling price is held roughly flat in real terms, reflecting continued tender pressure offsetting premium-material mix shift. For the forecast to hold, outpatient reimbursement policy must keep expanding at its recent pace and no major implant-related safety recall must disrupt bearing-surface adoption patterns.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs are back-tested against recorded procedure-volume and revenue growth over 2020-2024 in the markets with the most complete registry coverage, confirming the model reproduces the pandemic-year dip and subsequent recovery in elective procedure volume. Segment-level shifts, particularly the move toward outpatient settings and cementless fixation, were reviewed against clinician-reported adoption patterns rather than assumed to continue linearly. Sensitivities were tested on the pace of the outpatient shift and on average selling price under sustained tender pressure, since these two assumptions move the forecast total more than any procedure-volume assumption.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest for primary and revision procedure volume and pricing in the United States, Germany, Japan and the United Kingdom, where registry and reimbursement data are detailed and current. It is weaker for resurfacing procedures and for several Asia Pacific, Latin American and Middle Eastern markets, where registry coverage is partial or procedure-level reporting lags. A structural risk to this estimate is a material change in reimbursement policy for outpatient procedures, which would shift the application mix faster or slower than assumed. Overall confidence is assessed as medium rather than high given this data-quality spread.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Hip Replacement Devices Market projected to reach?
USD 13.8 Billion by 2034, CAGR 6.24%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 45% of global revenue through 2034.
05Which segment leads the market?
Primary HIP Replacement is the largest line by Type, at 68.5% of revenue in 2025.
06Who are the key companies profiled?
Zimmer, Smith & Nephew, DePuy Synthes, Waldemar LINK, Stryker, Corin, B. Braun, Medacta International, MicroPort Orthopedics, Exactech, Enovis, Limacorporate, Meril Life Sciences. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.